In relation to its share buy-back program, Sorin Group (Reuters Code: SORN.MI), a global leader in the treatment of cardiovascular diseases, announces that it has purchased, from November 8th, 2011 to November 11th, 2011, a total of 399,600 ordinary Sorin S.p.A. shares, equivalent to 0.0835% of the share capital, at an average unit gross price (including fees) of Euro 1.3562 per share, for a total consideration of Euro 541,918.

As of today, Sorin Group owns therefore n. 2,494,600 own shares, corresponding to 0.5211% of the share capital.

* * *

About Sorin Group

Sorin Group (www.sorin.com) is a global medical device company and a leader in the treatment of
cardiovascular diseases. The Company develops, manufactures, and markets medical technologies
for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,700 employees
worldwide, Sorin Group focuses on three major therapeutic areas that include: cardiopulmonary
bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management and
heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group
devices in more than 80 countries.

For more information, please visit: www.sorin.com, or contact:

Martine Konorski
Director, Corporate Communications
Tel: +33 (0)1 46 01 33 78
Mobile: +33 (0)6 76 12 67 73
e-mail: martine.konorski@sorin.com

Francesca Rambaudi
Director, Investor Relations
Tel: +39 02 69969716
e-mail: investor.relations@sorin 

.pdf